Robert Thomas Dechant - 16 Sep 2025 Form 4/A - Amendment Insider Report for IBEX Ltd (IBEX)

Reporting relationship: Chief Executive Officer, Director
Issuer ticker: IBEX
Reported as of: 16 Sep 2025
Net transaction value: $0
SEC form: 4/A - Amendment
Accepted by SEC: 13 Nov 2025, 17:10:54 UTC
Original report date: 17 Sep 2025
Prior SEC filing: 15 Sep 2025
Next SEC filing: 02 Oct 2025
Source filing: View source filing
Reporting owner signature: Lisa Lenstrohm, Attorney-in-Fact

Key filing fact

Robert Thomas Dechant filed Form 4/A - Amendment for IBEX Ltd (IBEX) on 13 Nov 2025.

Key facts

This page summarizes Robert Thomas Dechant's Form 4/A - Amendment filing for IBEX Ltd (IBEX).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 13 Nov 2025, 17:10.

Change

Previous filing in this sequence was filed on 15 Sep 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4/A - Amendment disclosures.

View source filing

Reporting Owners (1)

CIK 0001298255 Primary reporting owner

Dechant Robert Thomas

Relationship: Chief Executive Officer, Director
Address: C/O IBEX LIMITED, 1717 PENNSYLVANIA AVENUE NW, SUITE 825, WASHINGTON
Signature: Lisa Lenstrohm, Attorney-in-Fact
Signature date: 13 Nov 2025

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

IBEX transaction Derivative

Stock Option (Right to Buy Common Shares)

Options Exercise

Transaction value: $0
Shares: -45,027
Change %: -100%
Price: $0.000000
Shares after: 0
Date: 16 Sep 2025
Ownership: Direct
Underlying class: Common Shares
Underlying amount: 45,027
Exercise price: $19.00
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The acquisition and sale of the common shares underlying these options was previously reported on Form 4 on September 17, 2025. The exercise of the options was inadvertently not included in that Form 4 filing, so is now reported in this Amendment.

Footnote F2

The shares subject to this option are fully vested and exercisable.